PAPER Verma R, Kailashiya J, Mukherjee A, Chaurasia RN, Dash D

Prion protein fragment (106-126) activates NLRP3 inflammasome and promotes platelet-monocyte/neutrophil interactions, potentially contributing to an inflammatory state.

Front Cell Dev Biol. 2025;13:1534235. Epub 2025 Feb 25 PubMed.

PAPER Scotton WJ, Shand C, Todd EG, Bocchetta M, Kobylecki C, Cash DM, VandeVrede L, Heuer HW, Quaegebeur A, Young AL, Oxtoby N, Alexander D, Rowe JB, Morris HR, PROSPECT Consortium, Boxer AL, 4RTNI Consortium, Rohrer JD, Wijeratne PA

Distinct spatiotemporal atrophy patterns in corticobasal syndrome are associated with different underlying pathologies.

Brain Commun. 2025;7(2):fcaf066. Epub 2025 Feb 11 PubMed.

PAPER Writing Committee for the HEALEY ALS Platform Trial, Andrews J, Paganoni S, Macklin EA, Chibnik LB, Quintana M, Saville BR, Detry MA, Vestrucci M, Marion J, McGlothlin A, Young E, Chase M, Pothier L, Harkey B, Yu H, Sherman A, Shefner J, Hall M, Kittle G, Connolly MR, Berry JD, D'Agostino D, Tustison E, Giacomelli E, Scirocco E, Alameda G, Locatelli E, Ho D, Quick A, Heitzman D, Ajroud-Driss S, Appel SH, Shroff S, Katz J, Felice K, Maragakis NJ, Simmons Z, Goutman SA, Olney N, Miller T, Fernandes JA, Ilieva H, Jawdat O, Weiss MD, Foster L, Vu T, Ladha S, Owegi MA, Newman DS, Arcila-Londono X, Jackson CE, Swenson A, Heiman-Patterson T, Caress J, Fee D, Peltier A, Lewis R, Rosenfeld J, Walk D, Johnson K, Elliott M, Kasarskis EJ, Rutkove S, McIlduff CE, Bedlack R, Elman L, Goyal NA, Rezania K, Twydell P, Benatar M, Glass J, Cohen JA, Jones V, Zilliox L, Wymer JP, Beydoun SR, Shah J, Pattee GL, Martinez-Thompson J, Nayar S, Granit V, Donohue M, Grossman K, Campbell DJ, Qureshi IA, Cudkowicz ME, Babu S, HEALEY ALS Platform Trial Study Group

Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial.

JAMA Neurol. 2025 Feb 17; Epub 2025 Feb 17 PubMed.

A Hyeon Lee

Korea Brain Research Institute
, Korea, Republic of

Kaitlin Casaletto on Confirmed: Women Accumulate Tangles Faster Than Do Men

COMMENT This paper is a massive accomplishment, representing the most robust evidence yet of female-specific vulnerability to tau aggregation. Applying a meta-analytic approach, the authors pooled estimates across six studies, including more than 1,300 participan

Pierre Tariot on Confirmed: Women Accumulate Tangles Faster Than Do Men

COMMENT This strikes me as a thoughtful and rigorous effort to improve our understanding of the apparent increased risk of having a diagnosis of AD in women than men, the reasons for which are not fully elucidated. The authors make a compelling case that women ex

Confirmed: Women Accumulate Tangles Faster Than Do Men

RESEARCH NEWS 2025-03-12 Research News Numerous studies have hinted that women are particularly susceptible to tau pathology, but scientists have lacked definitive data. Now, a meta-analysis of six longitudinal tau PET studies offers the strongest evidence yet. In the March 3 JAM

Nicolai Franzmeier, Davina Biel on Confirmed: Women Accumulate Tangles Faster Than Do Men

COMMENT This meta-analysis by Coughlan et al. provides robust evidence across six longitudinal cohorts, showing that women accumulate tau pathology faster than men in preclinical AD. This work is of high clinical relevance, as the transition from amyloidosis to t

PAPER Xu X, Kwon J, Yan R, Apio C, Song S, Heo G, Yang Q, Timsina J, Liu M, Budde J, Blennow K, Zetterberg H, Lleó A, Ruiz A, Molinuevo JL, Lee VM, Deming Y, Heslegrave AJ, Hohman TJ, Pastor P, Peskind ER, Albert MS, Morris JC, Park T, Cruchaga C, Sung YJ

Sex Differences in Apolipoprotein E and Alzheimer Disease Pathology Across Ancestries.

JAMA Netw Open. 2025 Mar 3;8(3):e250562. PubMed.

Masoud Ghamari-Langroudi

United States

Meagan McManus on A positron emission tomography tracer for the imaging of oxidative stress in the central nervous system.

COMMENT I commend the authors for their exceptional characterization of the novel PET probe [18F]FEDV, which shows strong potential for detecting reactive oxygen species (ROS) in models of stroke and tauopathy. The validation of [18F]FEDV using dihydroethidium, t

Katia Lopes

Rush University Medical Center
United States

Meagan McManus

Children's Hospital of Philadelphia

Salete Lopes Ribeiro

Brazil

Tavapadon

THERAPEUTICS 1,5-dimethyl-6-[2-methyl-4-[3-(trifluoromethyl)pyridin-2-yl]oxyphenyl]pyrimidine-2,4-dione AbbVie Cerevel Therapeutics, LLC. Pfizer PF-06649751 CVL-751 Small Molecule Other Neurotransmitters From 2014 to 2016, Pfizer conduced Phase 1 trials of single- and